Glass House Brands (GLAS) Other financing activities (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Other financing activities of -$212000.0 for Q1 2026, up 29.33% year-over-year from -$163917.5 in Q1 2025, and down 12.17% quarter-over-quarter from -$189000.0 in Q4 2025.
Glass House Brands (GLAS) Other financing activities (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Other financing activities for 7 consecutive years, with -$212000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 29.33% year-over-year to -$212000.0; the TTM figure through Mar 2026 stood at -$254000.0 (up 29.83% YoY), while the FY2025 annual figure was -$342000.0, down 213.76% from the prior year.
- Other financing activities slipped to -$212000.0 in Q1 2026 per GLAS's latest filing, from -$189000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $54066.8 billion in Q4 2022 and bottomed at -$300000.0 in Q1 2025.
- Historically, Other financing activities has averaged $3604.5 billion across 5 years, with a median of -$44904.0 in 2023.
- Annual changes were most pronounced in 2022 — Other financing activities soared 42650205.21% — and 2025, when it plunged 612.9%.
- Glass House Brands' Other financing activities stood at $54066.8 billion in 2022, then plunged by 100.0% to $136682.0 in 2023, then tumbled by 122.68% to -$31000.0 in 2024, then plunged by 509.68% to -$189000.0 in 2025, then declined by 12.17% to -$212000.0 in 2026.
- Business Quant data shows GLAS's Other financing activities at -$212000.0 in Q1 2026, -$189000.0 in Q4 2025, and $368000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Glass House Brands | 837.25 Mn | 818.69 Mn | 15.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -212,000.00 |
| Mar 31, 2026 | -212,000.00 |
| Dec 31, 2025 | -189,000.00 |
| Dec 31, 2025 | -189,000.00 |
| Sep 30, 2025 | 368,000.00 |
| Sep 30, 2025 | 368,000.00 |
| Jun 30, 2025 | -221,000.00 |
| Jun 30, 2025 | -221,000.00 |
| Mar 31, 2025 | -300,000.00 |
| Mar 31, 2025 | -300,000.00 |
| Sep 30, 2024 | -31,000.00 |
| Sep 30, 2024 | -31,000.00 |
| Jun 30, 2024 | -31,000.00 |
| Jun 30, 2024 | -31,000.00 |
| Mar 31, 2024 | -47,000.00 |
| Mar 31, 2024 | -47,000.00 |
| Dec 31, 2023 | 136,682.00 |
| Dec 31, 2023 | 136,682.00 |
| Sep 30, 2023 | -45,470.00 |
| Sep 30, 2023 | -45,470.00 |